Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

SB 204269

Known as: SB-204269 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2001
2001
The effects of tonabersat (SB‐220453) were evaluated on trigeminal nerve ganglion stimulation‐induced sensory‐autonomic… Expand
2000
2000
SAR studies around a series of N-(tetrahydroisoquinolinyl)-2-methoxybenzamides, identified by high-throughput screening at the… Expand
2000
2000
SB-204269 (trans-(+)-6-acetyl-4S-(4-fluorobenzoylamino)-3, 4-dihydro-2,2-dimethyl-2H-benzo[b]pyran-3R-ol) shows anticonvulsant… Expand
1999
1999
The novel anticonvulsant SB-204269 inhibits epileptiform afterdischarges induced by high K+ in rat hippocampal slices. Its… Expand
1998
1998
On December 3, 1998, the Society for Medicines Research held a meeting entitled Trends in Medicinal Chemistry at the National… Expand
1998
1998
A series of N-(tetrahydroisoquinolinyl)-2-methoxybenzamides was identified by high-throughput screening at the novel SB-204269… Expand
1998
1998
  • F. Crespi
  • IDrugs : the investigational drugs journal
  • 1998
  • Corpus ID: 1653794
SB-204269 is an anticonvulsant agent under development by SmithKline Beecham, It is in phase II clinical trials as a potential… Expand
1997
1997
1 SB‐204269 (trans‐(+)‐6‐acetyl‐4S‐(4‐fluorobenzoylamino)‐3,4‐dihydro‐2,2‐dimethyl‐2H‐benzol[b]pyran‐3R‐ol, hemihydrate) shows… Expand
1997
1997
1 Earlier optimization of structure‐activity relationships in a novel series of 4‐(benzoylamino)‐benzopyrans, led to the… Expand
1997
1997
Departments of Neurosciences Research and*Medicinal Chemistry, SmithKline Beecham Pharmaceuticals, NewFrontiersSciencePark… Expand